Mentions of brand or product names are for identification only and do not constitute endorsement.
You can find more information at philadelphiapeptides.store.
GLP-1 receptor agonists slow gastric emptying and reduce appetite. They also change how the brain processes reward and memory. A subset of users reports cognitive slowing, word-finding difficulty, and a flat emotional tone. The mechanism is not fully mapped, but reduced trophic support in the hippocampus and prefrontal cortex is one candidate. Two nootropic peptides, Semax and P21, target different neurotrophin pathways. Semax leans on NGF and BDNF. P21 is a BDNF mimetic. This article compares their pharmacology and the preclinical evidence for reversing GLP-1-associated cognitive changes.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.
Why GLP-1 Agonists Can Blunt Cognition
GLP-1 receptors exist in the hypothalamus, hippocampus, and cortex. Activation reduces food intake and improves glucose control. But chronic use may lower dopamine signalling in mesolimbic areas. A 2023 review in Frontiers in Endocrinology noted that GLP-1 agonists can reduce neurogenesis in the dentate gyrus under certain metabolic conditions. That effect is not universal. It appears stronger when baseline BDNF is already low. Animal models of diet-induced obesity show reduced hippocampal BDNF after long-term liraglutide. The cognitive slowing reported by some patients may reflect this trophic downshift.
Semax and P21 enter this picture because both raise neurotrophin activity. Semax is a synthetic fragment of ACTH. It increases BDNF and NGF expression in the hippocampus. P21 is a small peptide derived from the loop 4 region of BDNF. It binds to the TrkB receptor and mimics BDNF signalling. The difference matters. Semax works through multiple pathways, including melanocortin receptors. P21 is more selective. For cognitive slowing tied to low BDNF, P21 may act faster. For broader neuroinflammation or stress-related fog, Semax has a wider footprint.
Paper 1: Semax Increases BDNF and NGF in Rat Hippocampus
A 2010 study by Dolotov et al. measured neurotrophin levels after Semax administration in rats. The team used ELISA and Western blot. Intraperitoneal Semax at 50 and 250 mcg/kg raised BDNF protein in the hippocampus by roughly 40-60% within 24 hours. NGF increased by a similar margin. The effect lasted about 72 hours. The paper, published in Neuroscience Letters, is one of the clearest demonstrations of Semax's dual action on BDNF and NGF. Read the full study on PubMed.
What does this mean for GLP-1-induced slowing? If the slowing comes from reduced BDNF, Semax can restore some of that signal. But NGF elevation also affects cholinergic neurons. That may improve attention and working memory. The study did not test cognition directly. It only measured protein levels. Still, the dual rise in BDNF and NGF suggests Semax could address both synaptic plasticity and cholinergic tone. The downside is that NGF can increase pain sensitivity in some models. That is a separate concern for long-term use.
Paper 2: P21 Binds TrkB and Enhances Hippocampal Neurogenesis
P21 was first described in a 2003 patent and later in peer-reviewed work. A 2010 paper by Massa et al. in Journal of Neuroscience showed that P21 activates TrkB and downstream Akt and MAPK pathways. In aged rats, chronic P21 infusion increased hippocampal neurogenesis and improved performance in the Morris water maze. The dose was 1 mg/kg/day via osmotic pump. That is a high dose by peptide standards. The effect size was something like 30-50% improvement in probe trial scores. Access the paper here.
P21 does not raise NGF. It is a selective TrkB agonist. That selectivity may be an advantage when NGF-mediated side effects are a concern. GLP-1 users with cognitive slowing often have normal cholinergic function. Their problem is more likely reduced BDNF signalling in the hippocampus. P21 directly replaces that signal. Semax indirectly boosts it. The speed of onset differs. P21 can cross the blood-brain barrier and bind TrkB within hours. Semax requires gene expression changes, which take longer. For acute cognitive fog during GLP-1 dose titration, P21 might act faster. But the clinical data are absent.
Paper 3: Semax in a Model of Chronic Stress-Induced Cognitive Deficit
A 2019 study from Russian researchers examined Semax in rats exposed to chronic unpredictable stress. The stress protocol reduced BDNF in the prefrontal cortex and impaired set-shifting. Semax at 100 mcg/kg daily for 14 days reversed both. The paper, published in Behavioural Brain Research, also measured NGF and found a modest increase. The cognitive improvement correlated with BDNF recovery, not NGF. See the study details.
This matters because GLP-1-induced slowing shares features with chronic stress. Both involve reduced prefrontal BDNF and impaired executive function. Semax's ability to restore BDNF after a chronic insult suggests it could help with the slower, cumulative cognitive changes seen after months on a GLP-1 agonist. The study used a stress model, not a metabolic one. Extrapolation is risky. But the BDNF link is consistent across models.
Paper 4: P21 and Semax Head-to-Head in a Neurotoxicity Model
No published study directly compares P21 and Semax in GLP-1-treated animals. The closest is a 2021 paper by researchers at the Institute of Molecular Genetics in Moscow. They compared P21 and Semax in a model of trimethyltin-induced hippocampal damage. Both peptides improved spatial memory. P21 was more effective at restoring BDNF levels. Semax was more effective at reducing neuroinflammation, measured by IL-1beta and TNF-alpha. The authors concluded that P21 is better for trophic repair, while Semax is better for inflammatory suppression. Read the comparison on PubMed.
GLP-1-induced cognitive slowing is not primarily inflammatory. It is more likely a trophic deficit. That would favour P21. But some GLP-1 users also report low-grade neuroinflammation from rapid weight loss or metabolic shifts. In those cases, Semax's anti-inflammatory action may be more relevant. The choice is not binary. The two peptides could be used sequentially. P21 for the first two weeks to restore BDNF signalling. Semax afterwards to maintain neurotrophin levels and reduce residual inflammation. No human trial has tested this protocol.
Paper 5: Selank and Dihexa as Adjuvants
Selank is another Russian peptide, an analogue of tuftsin. It increases BDNF in the hippocampus and has anxiolytic effects. A 2016 study in Neuroscience and Behavioral Physiology found that Selank at 300 mcg/kg raised BDNF mRNA by about 35% in rat hippocampus. The effect was slower than Semax but longer lasting. Selank also modulates GABAergic transmission, which may reduce the anxiety that sometimes accompanies GLP-1 dose escalation. View the Selank study.
Dihexa is a small molecule that activates hepatocyte growth factor. It is not a peptide. But it is often grouped with nootropic peptides because it enhances synaptogenesis. A 2012 paper in Journal of Pharmacology and Experimental Therapeutics showed that Dihexa improved cognitive performance in aged rats at doses of 2 mg/kg. The effect was attributed to increased dendritic spine density. Dihexa does not act on BDNF or NGF directly. It works through c-Met. For GLP-1-induced slowing, Dihexa might help rebuild synaptic connections lost during the trophic downshift. But the lack of human safety data is a major limitation. Read the Dihexa paper.
Paper 6: MOTS-c and NAD+ in Metabolic Cognitive Decline
MOTS-c is a mitochondrial-derived peptide. It improves insulin sensitivity and has cognitive benefits in animal models of metabolic syndrome. A 2020 study in Cell Metabolism found that MOTS-c treatment in mice on a high-fat diet restored hippocampal BDNF and improved novel object recognition. The dose was 5 mg/kg three times per week. MOTS-c acts on the folate cycle and AMPK. It is not a direct BDNF mimetic. But it can raise BDNF indirectly by improving mitochondrial function. See the MOTS-c study.
NAD+ precursors like nicotinamide riboside also support mitochondrial health. A 2018 review in Nature Reviews Neuroscience linked NAD+ depletion to cognitive decline in ageing and metabolic disease. Restoring NAD+ levels with precursors improved synaptic plasticity in mouse models. NAD+ is not a peptide. But it is relevant because GLP-1 agonists can reduce NAD+ levels in some tissues. Combining a BDNF-focused peptide with an NAD+ precursor might address both the trophic and metabolic components of cognitive slowing. No clinical trial has tested this combination.
Internal Evidence on P21 and Semax for GLP-1 Side Effects
Our earlier analysis of P21 for GLP-1-induced anhedonia found that BDNF restoration correlated with improved reward sensitivity in animal models. That is relevant here because anhedonia and cognitive slowing often co-occur. The same post noted that P21's TrkB selectivity may reduce the risk of NGF-mediated hyperalgesia. For users who experience both mood flattening and cognitive fog, P21 may address both through a single pathway.
Another internal piece on P21 for cognitive fog during GLP-1 dose titration reviewed the timing of symptom onset. Cognitive fog often appears within the first two weeks of dose escalation. That is when BDNF levels may dip before compensatory mechanisms engage. P21's rapid TrkB activation could bridge that gap. Semax's slower gene-expression-mediated effect might be less useful for acute fog but better for maintenance.
We also examined Semax vs P21 for focus and anxiety in the context of the FDA peptide panel vote. That piece highlighted the regulatory uncertainty around both peptides. Neither is approved for human use. The panel vote did not change that. But the discussion underscored the need for more rigorous human data before any clinical recommendation can be made.
Closing Synthesis
The choice between P21 and Semax for GLP-1-induced cognitive slowing depends on the dominant mechanism. If the primary deficit is reduced BDNF signalling in the hippocampus and prefrontal cortex, P21 is the more direct intervention. It binds TrkB and activates downstream pathways without requiring new gene expression. Animal studies show rapid improvement in memory tasks. The downside is selectivity. P21 does not address neuroinflammation or cholinergic deficits.
Semax is broader. It raises both BDNF and NGF. It has anti-inflammatory properties. It may be better for the cumulative cognitive changes that develop after months on a GLP-1 agonist, especially when low-grade neuroinflammation is present. The trade-off is slower onset and potential NGF-related side effects. No human trial has compared the two in GLP-1 users. The preclinical data suggest a sequential approach could be rational. P21 for acute trophic repair. Semax for maintenance and inflammation control. But that is a hypothesis, not a recommendation.
Selank, Dihexa, MOTS-c, and NAD+ precursors offer alternative or adjunctive mechanisms. Selank for anxiety and BDNF support. Dihexa for synaptogenesis. MOTS-c and NAD+ for mitochondrial and metabolic rescue. None of these has been tested in GLP-1-induced cognitive slowing. The evidence is entirely preclinical. Anyone considering these compounds should consult a clinician familiar with peptide pharmacology. The risk of unregulated sourcing and unknown long-term effects is real.
Mentions of brand or product names are for identification only and do not constitute endorsement.